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ABSTRACT:Hemochromatosis is a frequent genetic disorder, characterized by the accumulation of excess iron across
tissues. Mutations in the FPN1 gene, encoding a cell surface iron exporter [ferroportin (Fpn)], are responsible for
hemochromatosis type 4, also known as ferroportin disease. Recently, Fpn has been implicated in the regulation of
manganese (Mn), another essential nutrient required for numerous cellular enzymes. However, the roles of Fpn in
Mn regulation remain ill-defined, and the impact of diseasemutations on cellularMn levels is unknown. Here, we
provide evidence that Fpn can export Mn from cells into extracellular space. Fpn seems to play protective roles in
Mn-induced cellular toxicity and oxidative stress. Finally, disease mutations interfere with the role of Fpn in
controllingMn levels as well as the stability of Fpn. These results define the function of Fpn as an exporter of both
iron and Mn and highlight the potential involvement of Mn dysregulation in ferroportin disease.—Choi, E.-K.,
Nguyen, T.-T., Iwase, S., Seo, Y. A. Ferroportin disease mutations influence manganese accumulation and cyto-
toxicity. FASEB J. 33, 2228–2240 (2019). www.fasebj.org
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Hemochromatosis is a frequent hereditary iron metabo-
lism disorder characterized by the accumulation of excess
iron across tissues (1). Untreated hemochromatosis can be
fatal due to organ failure. The Online Mendelian In-
heritance inMan (OMIM; https://www.omim.org/) database
classifies 4 types of hemochromatosis (type 1 to type 4)
based on inheritance, genetic mutations, and clinical
manifestations of the disease. It is well established that
hemochromatosis mutations interfere with the function of
genes that control cellular iron levels [as reviewed by
Powell et al. (2)]. Homeostatic iron regulator HFE is a cell
surface iron sensor, and its mutations account for hemo-
chromatosis type 1. One of the hemochromatosis type 2
genes encodes hepcidin antimicrobial peptide HAMP,
which regulates the synthesis of a key iron homeostasis
factor called hepcidin. Transferrin receptor 2 (TFR2) mu-
tations are responsible for hemochromatosis type 3.
Transferrin receptor 2, a second receptor for serum
transferrin, incorporates transferrin-bound iron from
blood into cells (3). Finally, mutations in the FPN1 gene
cause an autosomal dominant form of hemochromatosis
type 4 (OMIM606069), also called ferroportin disease (4).
Ferroportin (Fpn), also known as MTP1, IREG1, or
SLC40A1 (UniProt AccessionNo. Q9NP59; OMIM604653;
https://www.uniprot.org/), is a transmembrane protein pre-
sent in the plasma membrane and is the only known cel-
lular iron exporter that has been identified in mammals
(5–7).Fpn isexpressed induodenal enterocytesandabsorbs
dietary iron, hepatic and splenic iron-recycling macro-
phages, and hepatocytes, where the transporter can export
stored iron when demand is high (6). Fpn is regulated by
hepcidin, which internalizes and degrades Fpn, thereby
decreasing the iron supply to plasma (8, 9). Similar to other
hemochromatosis types, long-term iron overload in ferro-
portin disease leads to a broad spectrum of pathologic
outcomes such as liver damage, including fibrosis and/or
cirrhosis, if left untreated.
Currently, .50 heterozygous mutations in the FPN1
gene have been associated with hemochromatosis type 4
(10).Mutations in theFPN1gene canresult in 2 subtypesof
this condition, type 4A and type 4B, depending on the
nature of the mutations. Hemochromatosis type 4A is the
classic ferroportin disease characterized by normal-to-low
transferrin saturation, which is an indicator of functional
blood iron level, and preferential iron retention in macro-
phages. This classic form of the disease is associated with
loss-of-function (LOF) Fpn mutations that interfere with
the iron export capability of Fpn. In contrast, hemochro-
matosis type 4B, also known as nonclassic ferroportin
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disease, is characterizedbyhigh transferrin saturation in the
blood along with iron accumulation, preferentially in he-
patocytes rather than macrophages. This nonclassic ferro-
portin disease is associatedwith the gain-of-function (GOF)
mutations that do not impair protein expression at the cell
membrane or its iron export activity but rather impair
hepcidin-induced Fpn degradation. Consistent with the
opposite consequences in blood iron levels, patients with
theGOFmutations (type4B/nonclassic) respondwell to the
conventional treatment of phlebotomy therapy, whereas
patients with the LOF mutations (type 4A/classic) become
anemic in response to phlebotomy therapy. No effective
treatment is available for hemochromatosis type 4A (4).
Although iron export activity of Fpn has been estab-
lished inmultiple experimentalmodels, includingXenopus
oocytes and HEK293T cells (5, 7, 11), studies have sug-
gested that Fpn can control cellular manganese (Mn) lev-
els. Using Xenopus oocytes, Madejczyk and Ballatori (12)
have shown that Fpn-expressing oocytes exported more
54Mn than control. Meanwhile, another group did not
observedetectableMnexportbyFpn in theXenopusoocyte
model, possibly due to a low baselineMn level within the
oocytes (13). The roles of Fpn in cellular Mn levels have
also been described in mammalian systems. Inducible
expression of Fpn in HEK293T cells reduced Mn accu-
mulation and toxicity (14). Fpn expression was elevated
when extracellular Mn levels increased in Caco-2 cells, a
cell culture model for intestinal absorption (15). However,
these studies in mammalian cells did not directly test the
efflux of Mn by Fpn. Therefore, the roles of Fpn in Mn
regulation remain incompletely understood.
Mn is an essential nutrient that functions as a cofactor
for the activity of numerous enzymes in cellular processes
(16). However, elevated levels of Mn can be toxic to cells
because they increase oxidative stress, impair mitochon-
drial function, and promote cell death (17, 18). Thus, in-
tracellular Mn levels must be tightly controlled to avoid
both excess and insufficiency. Although the role of Fpn in
Mnhomeostasis is beginning tobe appreciated, the impact
of ferroportin diseasemutations onMn accumulation and
toxicity remains unknown. Thus, the goal of the present
study was to define the role of Fpn in Mn regulation and
determine the functional consequences of ferroportin dis-
ease mutations in cellular Mn levels.
MATERIALS AND METHODS
Vector construction and site-directed
mutagenesis of Fpn
Human Fpn cDNAwas obtained from a cDNA clone (GenBank
accession number BC035893; National Center for Biotechnology
Information, Bethesda, MD, USA; https://www.ncbi.nlm.nih.gov/
genbank/). Theentirecodingregionof thewild-type (WT) formsof
human Fpnwere amplified and tagged at the C terminus with 2
tandem hemagglutinin (HA) epitopes by PCR using primers
FWD59-CCACCATGACCAGGGCGGGAGATCAC-39 andRev
59-GGCGTAGTCGGGGACGTCGTAGGGGTAGGCGTAGT-
CGGGGACGTCGTAGGGGTAAACAACAGATGTATTTG-
CTTG-39 and inserted into pcDNA3.1/V5-His TOPO vector
(Thermo Fisher Scientific,Waltham,MA,USA). Pointmutations
were introduced into this construct using the QuikChange
mutagenesis kit (Agilent Technologies, Santa Clara, CA, USA).
The site-directedmutation, orientation, and fidelity of the inserts
and incorporation of the epitope tags were confirmed by di-
rected sequencing (University of Michigan DNA Sequencing
Core, Ann Arbor, MI, USA).
Cell culture and the expression of Fpn and its
mutants in HEK293T cells
All culture media and supplements were purchased from
Thermo Fisher Scientific. Heat-inactivated fetal bovine serum
was purchased from MilliporeSigma (Burlington, MA, USA).
HEK293T cells and SH-SY5Y cells were grown in DMEM con-
taining 10% fetal bovine serum, penicillin (100 IU/ml), and
streptomycin (100 mg/ml) at 37°C in a humidified, 5% CO2 in-
cubator. DNA transfectionswere performedwith Lipofectamine
3000 (Thermo Fisher Scientific) according to the manufacturer’s
specifications. Cultures were generally transfected 24 h after
plating and used 48 h after transfection. For small interfering
RNA (siRNA)-mediated gene suppression of Fpn or SLC30A10,
SH-SY5Y cells were plated in 6-well plates overnight and then
transfected with 50 nM of control siRNA (SIC001-10NMOL;
MilliporeSigma), Fpn siRNA (SASI_Hs01_00224698; Milli-
poreSigma), or SLC30A10 siRNA (SASI_Hs01_00089069; Milli-
poreSigma) using Lipofectamine 3000 (Thermo Fisher Scientific)
as described earlier.
Immunofluorescence and microscopy
For confocal studies, transfected cells were plated onto glass
coverslips and fixed with 4% paraformaldehyde in PBS for
10 min, and immunofluorescence staining was performed as
previouslydescribed (19–21).Topermeabilize the cells, cellswere
incubated with 0.2% Triton X-100 in PBS for 5 min. Nonspecific
binding was blocked with 4% bovine serum albumin in PBS for
30 min, and transfected HA-tagged Fpn-WT or its mutants were
detected after incubationwithAlexa 488–conjugated anti-mouse
HA (90159, 1 mg/ml; BioLegend, San Diego, CA, USA) for 1 h.
Rabbit pan-cadherin (1 mg/ml, ab6529; Abcam, Cambridge,
United Kingdom) was used as cell surface markers. Detection of
pan-cadherin was performed by using an anti-rabbit IgG anti-
body conjugated to Alexa 568 (1 mg/ml, A11036; Thermo Fisher
Scientific) for 20 min. Coverslips were drained, mounted in
ProLong Gold (Thermo Fisher Scientific), and sealed with nail
polish. Immunofluorescent imaging was performed by using a
Nikon Eclipse A-1 confocal microscope (Nikon Instruments,
Melville,NY,USA)with a360oil immersion lens.Colocalization
analysis was performed after background subtraction through
the use of the colocalization function in Fiji by ImageJ (National
Institutes of Health, Bethesda, MD, USA), and colocalized pixels
were pseudocolored yellow. To quantify the subcellular locali-
zation of each mutant with pan-cadherin, statistical analysis of
the correlation of the intensity values of green and red pixels in a
dual-channel image was performed by using a correlation co-
efficient (Pearson’s coefficient). The value can range from+1 to21,
with +1 indicating a positive correlation,21 a negative correlation,
and 0 indicating no correlation (22).
Immunoblot analysis
The total lysateswere prepared in a hypotonic buffer by using 1%
NP-40 plus protease inhibitors (11836153001; Roche, Basel, Swit-
zerland). Protein concentrationwasdeterminedwith theBradford
assay. Samples (30–50mg) were separated by electrophoresis and
transferred to a nitrocellulose membrane (1620115; Bio-Rad,
Hercules, CA, USA). The membrane was immunoblotted with
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anti-mouseHAantibody (901501;BioLegend), anti-rabbitGPP130
antibody (923801; BioLegend), anti-mouse green fluorescent pro-
tein antibody (101536; Santa Cruz Biotechnology, Dallas, TX,
USA), and anti-mouse actin (60008-1-Ig; Proteintech, Rosemont,
IL, USA). The blots were visualized with infrared anti-mouse or
anti-rabbit secondary antibodies, using a Li-Cor Odyssey fluo-
rescent Western blotting system (Li-Cor, Lincoln, NE, USA).
Protein expression was quantified by using densitometry (Image
Studio Lite; Li-Cor).
54Mn and 59Fe accumulation and efflux assay
54Mn uptake assay was determined as previously described (21,
23, 24). Briefly, HEK293T cells were transfected with empty
vector (control), Fpn-WT, or mutants. Two days after trans-
fection, cells were incubated at 37°C for 30 min in serum-free
media containing 1 mM 54Mn. After uptake, cells were washed
3 times with PBS containing 1 mM EDTA to remove any un-
bound 54Mn and either directly harvested for intracellular ra-
dioactivity or used for the chase part of the experiment. Cells
were then transferred to HBSS without 54Mn and incubated at
37°C for 10min (chase phase). At the end of the chase, HBSSwas
collected to assessMnsecreted fromcells, andcellsweredigested
to assess intracellular Mn retained. For the 59Fe uptake assay,
HEK293T cells were transfected with empty vector (control) or
Fpn-WT. Two days after transfection, cells were incubated at
37°C for 60min in serum-freemediumcontaining 1mM59Fe and
150 mM L-ascorbic acid. After uptake, cells were washed 3 times
with PBS containing iron chelator solution (1 mM bath-
ophenanthroline sulfonate and 1 mM diethylenetriaminepenta-
acetic acid) to remove any unbound 59Fe; cells were then either
directly harvested for intracellular radioactivity or used for the
chasepart of the experiment. Cellswere then transferred toHBSS
containing 10 mM apo-transferrin (apo-Tf) and 6.6 nM soluble
human plasma ceruloplasmin without 59Fe and incubated at
37°C for 120 min (chase phase). Apo-Tf and soluble human
plasma ceruloplasmin were added as previously described (25).
At the end of the chase phase, HBSS was collected to assess iron
secreted from cells, and cells were lysed to assess intracellular
iron levels. Radioactivitywas determinedwith a gamma counter
and was normalized to the cell protein measured in lysates by
using the Bradford assay. The percentage of extracellular metal
levels over the total (intracellular + extracellular)metal levelswas
presented as an indicator for metal export activity.
Trace element analysis
HEK293T cells transfectedwith empty vector (control), Fpn-WT,
or mutants were analyzed for metals by inductively coupled
plasma mass spectrometry (ICP-MS) as previously described
(21). Briefly, the cell sampleswere digestedwith 2ml/g totalwet
weight nitric acid (AristarUltra; VWRInternational, Radnor, PA,
USA) for 24 h and then digested with 1 ml/g total wet weight
hydrogenperoxide (AristarUltra; BDHChemicals,Poole,United
Kingdom) for 24 h at room temperature. The samples were pre-
served at 4°C until quantification ofmetals. Ultrapurewater was
used for final sample dilution.
Measurement of ferritin
The intracellular ferritin level was measured by using a Human
Ferritin ELISA kit (ab108837; Abcam) according to the manu-
facturer’s instructions. Briefly, transfected cellswere treatedwith
20 mM ferric ammonium citrate for 16 h, and cell lysates were
thenprepared. Sampleswere incubatedwith biotinylated ferritin
antibody at room temperature, followed by the addition of
streptavidin-peroxidase conjugate and chromogen substrate.
Samples were read at 450 nm by using a BioTek Synergy HTX
Multi-Mode Microplate Reader (BioTek Instruments, Winooski,
VT, USA), and values were normalized according to protein
concentration.
Cell viability
Cell viability was measured by the conversion of the dye 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT;
MilliporeSigma) to formazan, as previously described (21, 26).
Briefly, the cells were incubated with MTT (0.5 mg/ml) for 3 h,
followed by addition of the MTT solvent (isopropyl alcohol
containing 0.1 N HCl) to dissolve the formazan. The resulting
formazan was assessed spectrophotometrically at 570 nm, and
the backgroundwas subtracted at 690 nmbyusing aplate reader
(BioTek Instruments).
Measurement of reactive oxygen species formation
Reactive oxygen species (ROS) levels were measured by using a
fluorescent indicator specific for H2O2 production [2’,7’-dichlor-
odihydrofluorescein diacetate (H2DCFDA)] as previously de-
scribed (21). H2DCFDA, a cell-permeant ROS indicator, is
nonfluorescent and then converted to highly fluorescent 29,79-
dichlorofluorescein (DCF) after the removal of the acetate
groups by intracellular esterases and ROS-induced oxidation.
Cells were incubated with 3 mMDCFH-DA (Thermo Fisher Sci-
entific) for30minat37°C.FluorescenceofDCF(excitation495nm,
emission 520 nm) was measured at 25°C by using a plate reader.
Statistical analysis
Results are presented as means 6 SD. Statistical comparisons
were determined by using Student’s t test with Prism 7 software
(GraphPad Software, La Jolla, CA,USA). Values ofP, 0.05were
considered statistically significant. Asterisks in graphs,wherever
present, denote statistically significant differences.
RESULTS
Impact of ferroportin disease mutations on
intracellular ferritin levels and localization
Thus far,.50 mutations in Fpn have been identified in he-
mochromatosis type 4/ferroportin disease (10). To test
whether these mutations alter cellular Mn metabolism, we
constructedanexpressionvector encodinghumanFpnwith
a C-terminal HA epitope tag and introduced 9 clinically
relevant mutations by site-directed mutagenesis (Table 1).
Based on previously reported in vitro functional results
(Table 2), we selected 5 ferroportin disease mutations from
eachof the 2groups: 5LOFmutations (G80S,R88G,D157G,
D157Y, and V162D) and 4 GOFmutations (N144H, N144T,
C326S, and S338R). Themutations and their positions in the
protein structure are summarized in Fig. 1A. G80S, N144H,
and N144T are located in predicted transmembrane
domains. R88G,D157G,D157Y, andV162D reside in the
intracellular domains, whereas C326S and S338R sub-
stitutions occur in extracellular domains.
We first sought to confirm the reported roles of Fpn and
its LOF andGOFmutants in the regulation of intracellular
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iron levels by measuring cytosolic iron storage protein
ferritin (Fig. 1B). Following the export of intracellular iron
by Fpn, intracellular iron should be depleted, thereby
leading to a reduction in intracellular ferritin concentra-
tions (27–29). Due to a low Fpn mRNA expression level,
HEK293T cells were ideal for detecting the impact of Fpn
cDNA overexpression. HEK293T cells were transiently
transfectedwith expressionplasmids for control, Fpn-WT,
or mutants and then incubated with 20 mM ferric ammo-
nium citrate. Subsequently, the intracellular ferritin levels
were determined by using ELISA. The expression of Fpn-
WTresulted in a reduction of;67% in intracellular ferritin
concentrations compared with the control cells. As
expected from previous reports (27–30), cells expressing
LOFmutants,G80S,R88G,D157G,D157Y,orV162Dwere
iron loaded, whereas the cells expressing GOF mutants
N144H, N144T, C326S, or S338R were iron depleted,
similar to those expressing Fpn-WT.
Previous research has shown that LOF Fpn mutants
failed to localize at the plasma membrane (29–31). Thus,
we next validated the reported mislocalization of Fpn
mutants. HEK293T cells expressing HA-tagged Fpn-
WT and mutants were costained with HA and the cell
surface marker pan-cadherin, and they were then ana-
lyzed by using confocal microscopy (Fig. 1C). As
expected, Fpn-WT exhibited significant overlap with
the cell surface marker pan-cadherin in addition to
some intracellular staining. The LOF mutants G80S,
R88G, D157G, D157Y, and V162D showed substantially
weaker or undetectable costainingwith pan-cadherin at
the cell surface. In contrast, the GOF mutants N144H,
N144T, C326S, and S338R displayed a similar staining
pattern as the Fpn-WT. Our measurement of Pearson’s
correlation coefficient (19, 22) revealed statistically
significant decreases in HA2cadherin colocalization
within the LOFmutant-expressing cells comparedwith
WT-expressing cells (P , 0.01, Fig. 1D). No significant
differences were found between the GOF mutant-
expressing cells, except C326S (P , 0.05). Taken to-
gether, these data indicate that the behavior of LOF and
GOF mutants in our experimental systems is similar to
that of previous reports (28, 29, 31–33).
TABLE 1. Summary of clinically known ferroportin disease mutations considered in the current study
Mutation Serum ferritin (mg/L)
Transferrin
saturation (%) Clinical phenotype Reference
WT 15–200 F; 40–300 M 15–45 both 56
G80S 519–702 F; 1200–3109 M 24–47 F; 35 M Loss of function 29
1540–4420 M 42–60 M 57
649–2434 M 25–28 F; 28–32 M 58
1233–2690 F; 966–1530 M 43
R88G 4129–4910 F; 2840 M 39–54 F Loss of function 29
8.2–44.5a 11–79a 30
2200 M 59
D157G 1590–6000 F; 4459 M 20–53 F; 35 M Loss of function 29
4069 M 44 M 60
D157Y 2213 M 35 M Loss of function 29
V162D 977–2578 F; 71.2–2268 M 14–35 F; 25–32 M Loss of function 29
4886 F; 2558 M 58
N144H 31–2179a 16–88.6a Gain of function 61
141.8–3108 M 50.4–100 M 62
N144T 2937 M 80 M Gain of function 63
C326S 151–299 F Gain of function 64
69–394 M 84–97 F; 86–94 M 65
S338R 1990 M 90 M Gain of function 33
F, female; M, male. aDid not specify sex.
TABLE 2. Summary of in vitro functional results of ferroportin disease mutations considered in the
current study
Mutation Cellular localization Iron transport Functional results Reference
WT Plasma membrane Normal 28
G80S Plasma membrane Impaired Loss of function 43
Intracellular 29
R88G Intracellular Impaired Loss of function 30
Plasma membrane 29
D157G Intracellular Impaired Loss of function 42, 29, 31
D157Y Intracellular Impaired Loss of function 29
V162D Intracellular Impaired Loss of function 28, 31
N144H Plasma membrane Normal Gain of function 28, 42
N144T Plasma membrane Normal Gain of function 32
C326S Plasma membrane Normal Gain of function 32
S338R Plasma membrane Normal Gain of function 33
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Figure 1. Effect of ferroportin disease mutations on intracellular ferritin levels and localization. A) A model of predicted topology
of Fpn based on previous studies (33, 55). Twelve transmembrane domains, intracellular NH2 and COOH terminus, and the
COOH terminal HA tag used in these experiments are described. Ten mutations identiﬁed in patients with ferroportin disease
examined in this study and the corresponding locations of these mutations are indicated as green text for LOF mutations and red
text for GOF mutations. B) HEK293T cells were transfected with empty vector (control), Fpn-WT, or Fpn mutants. After 48 h of
transfection, the cells were treated with ferric ammonium citrate (20 mM) for 16 h, and intracellular ferritin levels were measured
by using ELISA. The values were normalized according to protein concentration. C) Representative confocal images of
HEK293T cells expressing the HA-tagged Fpn-WT and its mutants are shown. To detect Fpn-WT and its mutants, the cells were
incubated with Alexa 488–conjugated anti-mouse HA antibody (green). To detect the cell surface, the cells were coincubated
with anti–pan-cadherin antibody followed by Alexa Fluor 568–conjugated secondary antibody (red). Merged images of HA and
pan-cadherin reveal areas of colocalization (yellow), indicated by arrows. Blue color indicates nuclei counterstained with DAPI.
Scale bar, 10 mm. D) Quantiﬁcation of Pearson’s coefﬁcient for colocalization between HA and calnexin from C. Results are
means6 SD of 3 independent experiments. The value of Pearson’s coefﬁcient can range from 1 to21, with 1 indicating complete
positive correlation and 21 a negative correlation, with zero indicating no correlation. *P , 0.05, **P , 0.01 between control
vector vs. Fpn-WT or between Fpn-WT vs. its mutants (Student’s t test).
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LOF mutations reduce Fpn stability
Althoughaprevious study reportedmislocalizationof Fpn
by the LOF mutations found in ferroportin disease, the
stability of mutant proteins remains unknown. To address
this issue, we performed immunoblot analysis of Fpn
recombinant proteins expressed in HEK293T cells. As
shown in Fig. 2, cells expressing Fpn-WT had a prominent
band at ;70 kDa and a less intense band at ;60 kDa.
Slower migration of the 70 kDa form in the gel has been
explainedbyN-linkedglycosylationof theprotein (34).The
LOF mutations G80S, R88G, D157G, D157Y, and V162D
resulted in substantially reducedprotein levels (Fig. 2A). In
particular, V162D showed increased accumulation of a
smaller molecular mass form. The GOFmutations did not
tend to alter protein levels, with one exception: S338R
exhibited reduced protein levels compared with WT.
Green fluorescent protein was included as a control of
transfection efficiency, indicating equal transfection effi-
ciencies of WT and Fpn mutants. These data indicate that
failure of localization at the plasmamembrane (Fig. 1C,D),
as well as the reduced overall protein level (Fig. 2B), col-
lectively lead to the inability of the LOFmutants to reduce
the intracellular iron levels seen in Fig. 1B.
Impact of ferroportin disease mutations on
intracellular Mn levels
Having established the correct behavior of LOF and GOF
mutants in ironexport,weproceededtoprobe the impactof
these mutations on cellular Mn levels. We first measured
Mn levels in cells expressing a control construct or Fpn-WT.
Mn measurements were performed by using ICP-MS and
after exposure of cells to 0–500mMMn for 16 h. Such levels
of Mn are not toxic to cells (26). Intracellular Mn levels in
cells expressing Fpn-WT were lower than those in control
cells (Fig. 3A), indicating that the expression of Fpn-WT
reduces cellular Mn levels. We also noted that intracellular
iron levels in cells expressing Fpn-WT tended to be lower
than those in control cells after exposure to 125 or 250 mM
Mn, although this reduction did not reach statistical sig-
nificance (Fig. 3B). The trend of reduced intracellular iron
levels may reflect the iron-exporting activity of Fpn in the
absence of higher iron exposure.We further testedwhether
theFpnmutant expression alters intracellularMn levels.As
shown in Fig. 3C, the expression of the LOFmutants G80S,
R88G, D157G, D157Y, and V162D failed to reduce Mn
levels compared with Fpn-WT expression (P , 0.01). In
contrast, the expression of the GOF mutants N144H,
N144T, C326S, and S338R showed similar levels of cellular
Mn comparedwith cells expressing Fpn-WT, indicating no
significant accumulation of Mn in the cells. No differences
wereobserved in cellular iron levels in cells expressingFpn-
WT or its mutants under these conditions (Fig. 3D).
We nextmeasured levels of theMn sensorGolgi protein
GPP130 (35). An increase in intra-Golgi Mn is known to
induce GPP130 trafficking from the Golgi to late endo-
somes and lysosomes, leading to GPP130 degradation.
Thus,wehypothesized that if Fpn-WTreduces intracellular
Mn levels, it would reduce the transport of Mn into the
Golgi, in turn inhibiting GPP130 degradation. The stability
ofGPP130wasassessedwithandwithoutMnCl2 treatment
by immunoblot. As expected, the level of GPP130 was
significantly reduced in control cells treated with Mn (Fig.
3E). Furthermore, this Mn-induced degradation was
blocked in cells expressing Fpn-WT. Quantification in-
dicated that;57% of GPP130 was lost after Mn treatment
in control cells,whereasno significantdecreasewas seen in
Fpn-WT–expressing cells (Fig. 3F). Importantly, expres-
sion of the LOFmutants G80S, R88G, D157G, D157Y, and
V162D did not prevent the Mn-induced loss of GPP130,
whereas expression of the GOF mutants N144H, N144T,
C326S, and S338R blocked GPP130 degradation. These
results indicate that the overexpression of Fpn-WT and the
GOFmutants resulted inMndepletion in thecells,whereas
the LOF mutations abrogated such an effect of Fpn.
Fpn is a Mn exporter, and disease mutations
interfere with its activity
To further define the roles of Fpn inMn regulation and the
impact of disease mutations, we administered radioac-
tively labeled 54Mn in cell culture media and then mea-
sured the accumulation ofMnwithin cells overexpressing
Fpn-WT or mutants. The overexpression of Fpn-WT
resulted in a decrease of ;45% (P , 0.01) in intracellular
Figure 2. Expression of Fpn-WT and mutations associated with
ferroportin disease. A) Representative immunoblot of HA-
tagged Fpn-WT and other mutants in total cell lysates isolated
from cells expressing empty vector (control), Fpn-WT, or Fpn
mutants. Green ﬂuorescent protein (GFP) is included as a
control for transfection efﬁciency. Immunoblot of actin was
used as a loading control. B) Quantiﬁcation of HA relative
protein after normalization with actin. Results are means 6 SD
(n = 3 samples/group) of 3 independent experiments. *P ,
0.05, **P , 0.01 between control vector vs. Fpn-WT or
between Fpn-WT vs. its mutants (Student’s t test).
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54Mn levels in the cells compared with control cells (Fig.
4A). TheLOFmutants displayed significantly higher 54Mn
levels compared with Fpn-WT (P , 0.01), indicating no
effect in reducing Mn levels in those cells. In contrast, the
overexpression of GOF mutants led to reduced 54Mn ac-
cumulation, similar to Fpn-WT.
The decrease in intracellular Mn levels and 54Mn ac-
cumulation in Fpn-WT–expressing cells can be caused by
either an increased Mn efflux or an impaired Mn uptake.
To segregate between these possibilities, pulse-chase as-
says were performed. Cells expressing control or Fpn-WT
constructs were transiently treated with 54Mn for 30 min
Figure 3. Effect of ferro-
portin disease mutations
on intracellular Mn levels.
A, B) HEK293T cells were
transfected with empty vec-
tor (control) or Fpn-WT
for 48 h. After treatment
with the indicated amounts
of Mn for 16 h, intracellu-
lar metal levels, including
Mn (A) and iron (B), were
measured by using ICP-MS.
C, D) HEK293T cells were
transfected with Fpn-WT
or other mutants for 48 h.
After treatment with 500 mM
Mn for 16 h, intracellular
metal levels, including Mn
(C) and iron (D), were
measured by using ICP-MS.
E) Representative immuno-
blot of GPP130 in total cell
lysates isolated empty vector
(control), Fpn-WT–, or its
mutant-expressing cells incu-
bated with 200 mM MnCl2
for 24 h. Equal loading was
veriﬁed by immunoblotting
with actin antibody. F)
Quantiﬁcation of GPP130
relative protein after nor-
malization with actin. Re-
sults are means 6 SD (n = 3
samples/group) of 3 inde-
pendent experiments. *P ,
0.05, **P , 0.01 vs. vehicle
(Student’s t test). N.s., not
signiﬁcant.
2234 Vol. 33 February 2019 CHOI ET AL.The FASEB Journal x www.fasebj.org
and then incubated with metal-free media for an addi-
tional 10 min. At the end of the metal-free incubation,
the amount of Mn retained in the cells and released into
the medium was measured by using a gamma counter.
Compared with control cells, Fpn-WT–expressing cells
retained less intracellular Mn and secreted more Mn into
themedia (Fig. 4B), indicating the increase ofMn efflux by
Fpn-WT overexpression. Similarly, in the pulse-chase as-
says using 59Fe (see theMaterials andMethods section for
details), Fpn-WT–expressing cells secreted more iron into
themedia thancontrol cells (Fig. 4C). Taken together, these
data indicate that Fpn exports both Mn and iron with
comparable efficiency.
We thenexamined the effluxactivityof cells expressing
Fpn mutants. Importantly, there was no difference in the
amount of Mn retained within the intracellular compart-
ment or released into the medium between control cells
and cells expressing the LOF mutants (Fig. 4D, E). The
GOF mutants displayed WT-equivalent Mn efflux activ-
ity. Taken together, these data show that Fpn can export
Mn from cells into extracellular space. In addition, the
LOF mutants, which are incapable of down-regulating
intracellular iron levels, were also defective in Mn efflux.
In contrast, theGOFmutationsdonot influence exports of
either iron or Mn.
Ferroportin disease mutations influence
Mn cytotoxicity
Elevated cellular levels of Mn can result in cytotoxicity
and increased oxidative stress (17, 18). The accumula-
tion of Mn by Fpn overexpression prompted us to test
whether the expression of ferroportin disease mutants
would affect Mn-induced cytotoxicity. We first treated
HEK293T cells expressing Fpn-WT or control cells with
Mn 0, 0.5, and 1 mM for 16 h and then measured their
viability by using the MTT assay. In control cultures,
the viability of cells treated with 0.5 or 1mMwas;79%
and;41%, respectively (Fig. 5A). Importantly, expression
Figure 4. Effect of ferroportin disease mutations on accumulation and efﬂux of 54Mn. A) HEK293T cells were transfected with
control, Fpn-WT, or mutants for 48 h and then incubated at 37°C for 30 min in the presence of 1 mM of 54Mn. Cells were chilled
on ice and washed with ice-cold PBS containing 1 mM EDTA; cell-associated radioactivity was determined by using a gamma
counter and was normalized to control vector–expressing cells. Data represent means 6 SD (n = 3 samples/group). B, C)
HEK293T cells were transfected with either control or Fpn-WT for 48 h, and the pulse-chase assay for Mn (B) and iron (C) was
performed as described in Materials and Methods. Percentage of extracellular metal levels over the total (intracellular +
extracellular) metal levels after the indicated duration of chase period is plotted. Data represent means 6 SD (n = 3 samples/
group). D, E) HEK293T cells were transfected with control, Fpn-WT, or mutants for 48 h, and the Mn pulse-chase assay was
performed as described earlier. Intracellular radioactivity retained and secreted after chase was normalized to 100 for control
cells. Results are means6 SD (n = 3 samples/group) of 3 independent experiments. *P, 0.05, **P, 0.01 between control vector
vs. Fpn-WT or between Fpn-WT vs. its mutants (Student’s t test).
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ofFpn-WTdidnothaveanyeffectoncell viabilitywithout
Mn treatment, although it protected against the Mn-
induced reduction of cell viability. In the absence of Mn
treatment, disease mutant expression also did not influ-
ence the MTT assay values (Fig. 5B). However, after Mn
treatment, the viability of cells expressing the LOF mu-
tants was significantly reduced by 46–63% compared
with Fpn-WT, whereas the GOF mutants exhibited a
protective effect against Mn-induced cytotoxicity, similar
to Fpn-WT (Fig. 5C).
To test whether the observed Mn cytotoxicity by fer-
roportindiseasemutations involvesROSproduction,ROS
levels were measured by using fluorescent indicators
specifically for H2O2 production (H2DCFDA). H2DCFDA
is converted to highly fluorescent 29,79-dichlorofluorescein
(DCF) following the removal of the acetate groups by in-
tracellular esterases and ROS-induced oxidation. In con-
trol cultures, Mn treatment in increasing concentrations
led to significantly higher DCF fluorescence (;18–48%)
(Fig. 5D). Expression of Fpn-WT protected against ROS
production that is induced by Mn but not under the ab-
sence of Mn. This Mn-dependent protective effect was
weaker in the 3 LOFmutantsG80S, R88G, andD157G and
not observed in the 2LOFmutantsD147YandV162D (Fig.
5E, F). In contrast, all the GOF mutants exhibited a pro-
tective effect againstMn-inducedoxidative stress (Fig. 5F).
Taken together, these data indicate that expression of
Fpn-WT and the GOF mutants protect cells from Mn cy-
totoxicity and Mn-induced oxidative stress, whereas the
LOF mutants fail to exert such a protective function.
Knockdown of Fpn increases intracellular Mn
levels and exacerbates Mn cytotoxicity
In addition to the effects of Fpn-WT overexpression in
HEK293T cells,we sought to testwhether endogenous Fpn
is necessary for maintaining lower Mn levels in the cells.
We tookadvantageof the endogenous expressionofFpn in
SH-SY5Y human neuroblastoma cells. SH-SY5Y cells are a
third-generation subclone of the SK-SN-SH dopaminergic
neuroblastoma cell line derived from the brain (36) and
have been extensively used for studies on Mn toxicity,
mitochondrial dysfunction, and neuronal cell death in-
duced by oxidative stress (26, 37, 38). To test the effect of
Fpndepletionon the cell viability,weused siRNAtoknock
down Fpn in SH-SY5Y cells. RT-PCR analysis showed that
Fpn is effectively reduced by ;76% (P , 0.01) compared
with cells transfected with a control siRNA, which should
not target any human gene (Fig. 6A). Knockdown of Fpn
did not affect cell viability in the absence of Mn (Fig. 6B).
However, after a 16 h exposure to 0.25 and 0.5mMMn, the
viability of Fpn-depleted cells was significantly less than
that of cells transfected with the control siRNA.
Figure 5. Effect of ferroportin disease mutations on Mn cytotoxicity. A) HEK293T cells were transfected with control or Fpn-WT.
Two days after transfection, cells were exposed to 0.5 and 1 mM of Mn2+ for 16 h. Cell viability was determined by using the MTT
assay. B, C) HEK293T cells expressing control, Fpn-WT, or its mutants were left untreated (B) or exposed (C) to 1 mM of Mn2+
for 16 h. Cell viability was determined by using the MTT assay. D) HEK293T cells were transfected with control or Fpn-WT. Two
days after transfection, cells were exposed to 0.5 and 1 mM of Mn2+ for 16 h. Intracellular ROS formation was measured by using
DCF ﬂuorescence. E, F) HEK293T cells expressing control, Fpn-WT, or its mutants were left untreated (E) or exposed (F) to
1 mM of Mn2+ for 16 h. Intracellular ROS formation was measured by using DCF ﬂuorescence. Data represent means 6 SD as a
percentage of Fpn-WT (n = 5 samples/group). *P , 0.05, **P , 0.01 between control vector vs. Fpn-WT or between Fpn-WT vs.
its mutants (Student’s t test). Similar results were obtained in at least 3 independent experiments.
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Furthermore, the knockdown of Fpn significantly in-
creasedH2O2 production after a 16 h exposure to 0.25mM
Mn (Fig. 6C). The knockdown results complement our
overexpression studies and indicate that FpnmediatesMn
detoxification.
Studies have shown that SLC30A10 is a cell surface–
localized, Mn-efflux transporter (39, 40). To evaluate the
contribution of endogenous SLC30A10 in SH-SY5Y cells,
we compared the mRNA levels of endogenous Fpn and
SLC30A10 in SH-SY5Y cells. The reported RNA-seq data
of SH-SY5Y cells indicated that Fpn expression was ;12-
fold higher than SLC30A10 (1.85 vs. 0.15 fragments/kb of
exon model per million mapped reads) (41). To test the
effect of SLC30A10 depletion on cell viability, we used
siRNA to knock down SLC30A10 in SH-SY5Y cells. RT-
PCR analysis revealed that SLC30A10 is effectively re-
duced by ;70% (P , 0.01) (Fig. 6D). Knockdown of
SLC30A10 did not affect cell viability in the absence ofMn
(Fig. 6E). However, the knockdown of SLC30A10 signifi-
cantly decreased cell viability after a 16 h exposure to
0.25 and 0.5 mM Mn. Furthermore, the knockdown of
SLC30A10 significantly increased H2O2 production
after a 16 h exposure to 0.25 mM Mn (Fig. 6F). These
results indicate that similar to Fpn, SLC30A10,
despite its low-level expression, can mediate Mn de-
toxification in SH-SY5Y cells.
DISCUSSION
The present report describes the first in vitro functional
analysis of human Fpnmutations inMn accumulation and
cytotoxicityResults are summarized inTable3.We initially
found differential consequences of these mutations on the
cellular localization and stability of Fpn by examining the
behavior of 5 LOF mutants and 4 GOF mutants of Fpn in
HEK293T cells. Studies have shown that the LOF muta-
tions,which leadpatients to exhibit the classicphenotypeof
Kupffer cell ironaccumulation, affect the localizationofFpn
on the cell surface. Consistently, several studies reported
intracellular localizationof theG80S,R88G,D157G,D157Y,
and V162D Fpn mutants (28–31, 42). However, other
studies found localization of G80S (43), R88G (29), D157G,
and V162D (44), primarily at the cell surface. Our cellular
localization studies supported the notion that the LOF
mutants are localized intracellularly, although some cell
surface staining was detected. These somewhat in-
consistent observations may be partially explained by the
Figure 6. Fpn protects against Mn-induced toxicity in dopaminergic SH-SY5Y cells. A, D) SH-SY5Y cells were transfected with
control (scRNA) or anti-Fpn siRNAs (siFpn) or anti-SLC30A10 siRNAs (siSLC30A10). Down-regulation of siFpn (A) or
siSLC30A10 (D) was conﬁrmed by semi-quantitative RT-PCR 48 h after the transfection of each siRNA. B, E) Twenty-four hours
after knockdown, cells were left untreated or exposed to Mn2+ for an additional 16 h. Cell viability was assessed by using the MTT
assay. C, F) Twenty-four hours after knockdown, cells were left untreated or exposed to Mn2+ for an additional 16 h.
Intracellular ROS formation was measured by using DCF ﬂuorescence. Data represent means 6 SD (n = 6–8 samples/group).
*P , 0.05, **P , 0.01 vs. scRNA-transfected cells (Student’s t test). Similar results were obtained in at least 3 independent
experiments. N.s., not signiﬁcant.
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use of different cell lines and the presence or absence of
cycloheximide, an inhibitor of protein synthesis, in the as-
say system (33). In contrast, with regard to the GOF mu-
tations that lead to the nonclassic phenotype of hepatocyte
iron accumulation, most studies have shown consistent
results of cell surface staining, similar to our observation. In
addition to the mislocalization, we found that LOF mu-
tants but not GOF mutants were unstable (Fig. 2). Thus,
overall reduction of Fpn protein levels by the mutations
might be another contributing factor to classic ferro-
portin disease.
In this study, we provided several lines of evidence for
Fpn’s roles in Mn export and the deleterious consequences
of disease mutations. First, we described the decreased in-
tracellularMn levels upon Fpn-WT overexpression by ICP-
MS (Fig. 3A–D). Second, we validated the intracellular Mn
levelsbyperforming theGPP130degradationassay (Fig. 3E,
F). Third, we showed that the decrease in intracellular Mn
levels in Fpn-WT and the GOF mutants was due to an in-
crease inMn efflux (Fig. 4). Fourth, Fpn-WToverexpression
was protective to Mn-induced cell toxicity and ROS
production, whereas Fpn depletion sensitized cells to
Mn-dependent oxidative stress (Figs. 5 and 6). Direct mea-
surement of iron efflux has been difficult inmammalian cells.
In this study, we were able to detect Fpn-mediated iron
effluxusing themodifiedeffluxassay (Fig. 4C). Basedonour
pilot experiments, we found that iron requires longer du-
rations of both pulse and chase phases than Mn (data not
shown). The differences can be explained by the distinct
cellular traffickingmechanisms of the 2metals. Once inside
cells, iron is either deposited in ferritin or incorporated into
the mitochondria for heme metabolism and synthesis of
iron-sulfur clusters. Thus, iron is not readily available for
export, and the export activity of Fpn is dependent on the
iron’s metabolic response. In contrast, Mn exists in a more
labile pool that is readily available for export and is inde-
pendent of the iron’s metabolic response. Because of these
differences, we cannot formally compare efflux rate of the 2
metals by Fpn in any cell-based assays. As such, it remains
unclear whether Fpn prefers one metal over the other in
general or in certain contexts. Nonetheless, our data show
that Fpn can export both Mn and iron, and the disease
mutations influence export activities of bothmetals. Further
studies will be required to test whether there are key
functional amino acids of Fpn that specifically contribute to
iron and Mn export activity.
With regard to disease mechanisms, it is important to
note that our overexpression experiment and knockdown
study do not accurately generalize to the status in patient
cells, as disease mutations are heterozygous. It has been
proposed that the mutant Fpn protein can act as a domi-
nant negative form over the WT-Fpn (10). Although the
present study does not rule out the dominant negative
mechanisms, it provides evidence that patient mutations
negatively affect the intrinsic activity of Fpn as an exporter
of iron andMn. In a recent study,we characterized flatiron
mice, in which Fpn carries the heterozygous H32R muta-
tion and fails to localize at the plasma membrane (26).
Flatiron mice display lower Mn levels in the blood and
liver and Mn accumulation in the brain (26, 45). Collec-
tively, these observations led us to predict that the classic
ferroportin disease/hemochromatosis type 4A,which has
been deemed to be solely an iron-overload condition, in-
volves Mn dysregulation.
It is noteworthy that Mn overload preferentially affects
the brain (46). Exposure to elevated levels of Mn results in
metal accumulation in specific brain regions associated
with parkinsonian motor dysfunction (47, 48). In addition
to macrophages of the reticuloendothelial system, intesti-
nal duodenum, and hepatocytes (6), Fpn is ubiquitously
expressed in the brain, including neurons, astrocytes, the
endothelial cells of the blood–brain barrier, oligodendro-
cytes, the choroid plexus, and ependymal cells (49, 50).
Genetic mutations in S\LC30A10, a cell-surface Mn ex-
porter gene, were reported in a new form of Mn-induced
parkinsonism (51, 52). SLC30A10 is highly expressed in
the liver and brain tissues (53) and protects cells against
Mn toxicity (39, 54) (Fig. 6). It remains unknown where
and how Fpn and SLC30A10 interplay in response to the
brain’s demands for metal. To date, no neurologic
symptoms have been reported in patients with ferro-
portin disease. Our study raises the possibility that pa-
tients with ferroportin disease mutations may be more
susceptible to Mn neurotoxicity. Further studies are
warranted to evaluate the relevance of ferroportin dis-
ease mutations to Mn metabolism and neurotoxic-
ity associated with metal exposure in the human
population.
TABLE 3. Summary of in vitro functional studies of ferroportin disease mutations
Mutation Cellular localization Intracellular Mn
GPP130
degradation
54Mn
accumulation 54Mn efﬂux
Mn-induced
cell toxicity Mn-induced ROS
WT Plasma membrane Normal Blocked Decreased Increased Protective Reduced
G80S Intracellular Increased Not blocked Increased Decreased Not protective Increased
R88G Intracellular Increased Not blocked Increased Decreased Not protective Increased
D157G Intracellular Increased Not blocked Increased Decreased Not protective Increased
D157Y Intracellular Increased Not blocked Increased Decreased Not protective Reduced
V162del Intracellular Increased Not blocked Increased Decreased Not protective Reduced
N144H Plasma membrane Normal Blocked Decreased Increased Protective Reduced
N144T Plasma membrane Normal Blocked Decreased Increased Protective Reduced
C326S Plasma membrane/
intracellular
Normal Blocked Decreased Increased Protective Reduced
S338R Plasma membrane Normal Blocked Decreased Increased Protective Reduced
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